MediWound Ltd. is a biotechnology niche specialty company. Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burns, hard to heal and chronic wound management.
MediWound’s goal is to provide healthcare professionals and patients with its innovative burn wound eschar removal agent NexoBrid™. This uniquely differentiated and innovative product have successfully completed clinical development and is approved and launched throughout Europe.
MediWound’s innovative medicinal product, NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial-and full-thickness thermal burns.
MediWound operates a cGMP and ISO-13485 manufacturing facility for sterile pharmaceutical products and medical devices that meets high quality requirements.
For more information about MediWound, please visit: www.mediwound.com